Cancer Discov. 2017 Sep;7(9):927. doi: 10.1158/2159-8290.CD-ND2017-004. Epub 2017 Aug 4.
In a recent trial, the PD-1 inhibitor nivolumab failed to outperform chemotherapy as a first-line treatment for non-small cell lung cancer, even though another PD-1 inhibitor, pembrolizumab, was shown to be an effective treatment just months earlier. Researchers attribute these surprising results to differences in patient selection in the two trials, and suggest that the discovery of better biomarkers, among other strategies, might allow more patients to benefit from immunotherapies.
在最近的一项试验中，PD-1 抑制剂纳武利尤单抗未能超越化疗，成为非小细胞肺癌的一线治疗药物，尽管就在数月前，另一种 PD-1 抑制剂帕博利珠单抗已被证明是一种有效的治疗药物。研究人员将这些令人惊讶的结果归因于两项试验中患者选择的差异，并提出发现更好的生物标志物等策略可能会使更多患者受益于免疫疗法。
